Using TGF-α-stimulated cells and a mouse model, the authors also observed that MEK inhibition prevents progression of established fibrosis and provides an attractive target for targeting the MEK pathway in fibrotic lung disease [45], as well as suggests that metabolic pathways are molecular mechanisms closely associated with IPF pathogenesis. Here, TGFA is linked to lung disorder.